Publicaciones en colaboración con investigadores/as de Universitat de Barcelona (33)

2023

  1. The CARBA-MAP study: national mapping of carbapenemases in Spain (2014–2018)

    Frontiers in Microbiology, Vol. 14

2022

  1. A systematic literature review and expert consensus on risk factors associated to infection progression in adult patients with respiratory tract or rectal colonisation by carbapenem-resistant Gram-negative bacteria

    Revista Espanola de Quimioterapia, Vol. 35, Núm. 5, pp. 455-467

  2. Hidden dissemination of carbapenem-susceptible OXA-48-producing Proteus mirabilis

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 11, pp. 3009-3015

2021

  1. Invasive aspergillosis in solid organ transplantation: Diagnostic challenges and differences in outcome in a Spanish national cohort (Diaspersot study)

    Mycoses, Vol. 64, Núm. 11, pp. 1334-1345

  2. Uptake of ozenoxacin and other quinolones in gram-positive bacteria

    International Journal of Molecular Sciences, Vol. 22, Núm. 24

2020

  1. Comparative activity of ozenoxacin and other quinolones in Staphylococcus aureus strains overexpressing the efflux pump-encoding genes mepA and norA

    International Journal of Antimicrobial Agents, Vol. 56, Núm. 3

  2. Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with hematological malignancies

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 4, pp. 174-181

  3. Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 4, pp. 182-187

2019

  1. Microbiological profile of ozenoxacin

    Future Microbiology, Vol. 14, Núm. 9, pp. 773-787

  2. Mutant prevention concentration of ozenoxacin for quinolone-susceptible or - resistant Staphylococcus aureus and Staphylococcus epidermidis

    PLoS ONE, Vol. 14, Núm. 10

  3. Ozenoxacin: a review of preclinical and clinical efficacy

    Expert Review of Anti-Infective Therapy, Vol. 17, Núm. 3, pp. 159-168

2018

  1. Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations

    Transplantation Reviews, Vol. 32, Núm. 1, pp. 36-57

2017

  1. European Respiratory Society guidelines for the management of adult bronchiectasis

    European Respiratory Journal, Vol. 50, Núm. 3

2016

  1. Escherichia coli: An old friend with new tidings

    FEMS Microbiology Reviews, Vol. 40, Núm. 4, pp. 437-463

  2. Estudios de coste-efectividad con MALDI-TOF e impacto clínico

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 34, pp. 47-52

  3. High Body Mass Index as a Risk Factor for Hospitalization Due to Influenza: A Case-Control Study

    Archivos de Bronconeumologia, Vol. 52, Núm. 6, pp. 299-307

2015

  1. Evaluation of the eazyplex® SuperBug CRE system for rapid detection of carbapenemases and ESBLs in clinical Enterobacteriaceae isolates recovered at two Spanish hospitals

    Journal of Antimicrobial Chemotherapy, Vol. 70, Núm. 4, pp. 1047-1050

  2. In vitro selection of mutants resistant to ozenoxacin compared with levofloxacin and ciprofloxacin in Gram-positive cocci

    Journal of Antimicrobial Chemotherapy, Vol. 70, Núm. 1, pp. 57-61

  3. Streptococcus gallolyticus subsp. gallolyticus from human and animal origins: Genetic diversity, antimicrobial susceptibility, and characterization of a vancomycin-resistant calf isolate carrying a vanA-Tn1546-like element

    Antimicrobial Agents and Chemotherapy, Vol. 59, Núm. 4, pp. 2006-2015

2014

  1. Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013

    Journal of Hepatology